Knight Therapeutics to commit $27 mln to Dutch VC fund
Canadian specialty pharmaceutical company Knight Therapeutics Inc (TSX: GUD) has agreed to commit EUR 19.5 million ($27.5 million) to the third life sciences fund managed by Dutch venture capital firm Forbion Capital Partners. The commitment, which follows an earlier commitment to a life sciences fund managed by Sectoral Asset Management, expands Knight's product sourcing strategy for the Canadian market, the company said. Knight plans to commit up to $130 million to this strategy. Forbion this month announced a first close of Forbion Capital Fund III CV at EUR 92 million ($129.6 million).
3 October 2014•4 mins read
